Similar articles for PMID: 16614241

Year	Number of Results
2002	1
2003	1
2004	4
2005	11
2006	14
2007	30
2008	27
2009	32
2010	33
2011	34
2012	37
2013	25
2014	29
2015	5
2016	11
2017	12
2018	8
2019	10
2020	9
2021	11
2022	20
2023	8
2024	0

1

Bcr-Abl resistance screening predicts a limited spectrum of point mutations to be associated with clinical resistance to the Abl kinase inhibitor nilotinib (AMN107).

von Bubnoff N, Manley PW, Mestan J, Sanger J, Peschel C, Duyster J. von Bubnoff N, et al. Blood. 2006 Aug 15;108(4):1328-33. doi: 10.1182/blood-2005-12-010132. Epub 2006 Apr 13. Blood. 2006. PMID: 16614241 Free article.

2

Dynamic change of T315I BCR-ABL kinase domain mutation in Korean chronic myeloid leukaemia patients during treatment with Abl tyrosine kinase inhibitors.

Kim WS, Kim D, Kim DW, Kweon IY, Kim SH, Goh HG, Park SH, Lee J. Kim WS, et al. Hematol Oncol. 2010 Jun;28(2):82-8. doi: 10.1002/hon.918. Hematol Oncol. 2010. PMID: 19768693

3

New Bcr-Abl inhibitors in chronic myeloid leukemia: keeping resistance in check.

O'Hare T, Eide CA, Deininger MW. O'Hare T, et al. Expert Opin Investig Drugs. 2008 Jun;17(6):865-78. doi: 10.1517/13543784.17.6.865. Expert Opin Investig Drugs. 2008. PMID: 18491988 Review.

4

Sequential inhibitor therapy in CML: in vitro simulation elucidates the pattern of resistance mutations after second- and third-line treatment.

Bauer RC, Sänger J, Peschel C, Duyster J, von Bubnoff N. Bauer RC, et al. Clin Cancer Res. 2013 Jun 1;19(11):2962-72. doi: 10.1158/1078-0432.CCR-13-0052. Epub 2013 Apr 2. Clin Cancer Res. 2013. PMID: 23549879

5

A cell-based screen for resistance of Bcr-Abl-positive leukemia identifies the mutation pattern for PD166326, an alternative Abl kinase inhibitor.

von Bubnoff N, Veach DR, van der Kuip H, Aulitzky WE, Sänger J, Seipel P, Bornmann WG, Peschel C, Clarkson B, Duyster J. von Bubnoff N, et al. Blood. 2005 Feb 15;105(4):1652-9. doi: 10.1182/blood-2004-06-2445. Epub 2004 Sep 30. Blood. 2005. PMID: 15459011 Free article.

6

BCR-ABL kinase domain mutations, including 2 novel mutations in imatinib resistant Malaysian chronic myeloid leukemia patients-Frequency and clinical outcome.

Elias MH, Baba AA, Azlan H, Rosline H, Sim GA, Padmini M, Fadilah SA, Ankathil R. Elias MH, et al. Leuk Res. 2014 Apr;38(4):454-9. doi: 10.1016/j.leukres.2013.12.025. Epub 2014 Jan 6. Leuk Res. 2014. PMID: 24456693

7

Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic phase.

Hughes T, Saglio G, Branford S, Soverini S, Kim DW, Müller MC, Martinelli G, Cortes J, Beppu L, Gottardi E, Kim D, Erben P, Shou Y, Haque A, Gallagher N, Radich J, Hochhaus A. Hughes T, et al. J Clin Oncol. 2009 Sep 1;27(25):4204-10. doi: 10.1200/JCO.2009.21.8230. Epub 2009 Aug 3. J Clin Oncol. 2009. PMID: 19652056 Free PMC article. Clinical Trial.

8

Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study.

Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Ray A, et al. Blood. 2007 Jun 1;109(11):5011-5. doi: 10.1182/blood-2006-01-015347. Epub 2007 Feb 15. Blood. 2007. PMID: 17303698 Free article.

9

The ABL switch control inhibitor DCC-2036 is active against the chronic myeloid leukemia mutant BCR-ABLT315I and exhibits a narrow resistance profile.

Eide CA, Adrian LT, Tyner JW, Mac Partlin M, Anderson DJ, Wise SC, Smith BD, Petillo PA, Flynn DL, Deininger MW, O'Hare T, Druker BJ. Eide CA, et al. Cancer Res. 2011 May 1;71(9):3189-95. doi: 10.1158/0008-5472.CAN-10-3224. Epub 2011 Apr 19. Cancer Res. 2011. PMID: 21505103 Free PMC article.

10

Frequency of ABL gene mutations in chronic myeloid leukemia patients resistant to imatinib and results of treatment switch to second-generation tyrosine kinase inhibitors.

Marcé S, Zamora L, Cabezón M, Xicoy B, Boqué C, Fernández C, Grau J, Navarro JT, Fernández de Sevilla A, Ribera JM, Feliu E, Millá F; Grupo ICO de estudio de mutaciones de ABL en pacientes afectos de LMC. Marcé S, et al. Med Clin (Barc). 2013 Aug 4;141(3):95-9. doi: 10.1016/j.medcli.2012.10.028. Epub 2013 Feb 22. Med Clin (Barc). 2013. PMID: 23433665

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

316 results

Results by year